Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women
Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women
复制标题
DOI：
10.1200/jco.2001.19.2.322
复制
发表时间：
2001-01-15
影响因子：
45.3
通讯作者：
Lash, TL
中科院分区：
文献类型：
--
作者：
Demissie, S;Silliman, RA;Lash, TL
用途：为了确定预测辅助他莫昔芬的使用，副作用，并停止在老年women.Patients和方法：我们遵循了一个队列的303名妇女大于或等于55岁诊断为I期或II期乳腺癌近3年。数据收集从妇女的手术记录和计算机辅助电话采访后5，21，和33个月的原发性肿瘤therapy.Results：二百九十二（96%）的303例患者在研究中提供有关他莫昔芬使用的信息。189例患者（65%）报告使用他莫昔芬; 26例（15%）在随访VP期间停用。65至74岁（相对于55至64岁）的患者，患有II期疾病，雌激素受体阳性，看过更多的乳腺癌医生，并且对自己与医生讨论治疗方案的能力有更好的认识，使用他莫昔芬的几率更大。那些身体机能较好，接受过标准原发性肿瘤治疗，并从书籍或杂志中获得有用的乳腺癌信息的人使用他莫昔芬的几率较小。≥ 75岁的患者（相对于55至64岁）和情绪健康状况较好的患者报告副作用的几率明显较低，雌激素受体阳性的患者不太可能停止服用他莫昔芬;经历副作用的患者更可能停止服用他莫昔芬。偏离辅助他莫昔芬的处方疗程相对频繁，这种偏离的临床后果需要确定。J Clin Oncol 19：322-328. (C)2001年，美国临床肿瘤学会。
Purpose: To identify predictors of adjuvant tamoxifen use, side effects, and discontinuation in older women.Patients and Methods: We followed a cohort of 303 women greater than or equal to 55 years of age diagnosed with stage I or stage II breast cancer for nearly 3 years. Data were collected from women's surgical records and from computer-assisted telephone interviews at 5, 21, and 33 months after primary tumor therapy.Results: Two hundred ninety-two (96%) of 303 patients in the study provided information about tamoxifen use. Tamoxifen use was reported by 189 patients (65%); 26 (15%) discontinued use during the follow-vp period. Patients who were 65 to 74 years of age (relative to those 55 to 64 years of age), held stage II disease, were estrogen receptor-positive, saw a greater number of breast cancer physicians, and had better perceptions of their abilities to discuss treatment options with physicians had greater odds of tamoxifen use. Those who had better physical function, had received standard primary tumor therapy, and had obtained helpful breast cancer information from books or magazines had lesser odds of tamoxifen use. patients greater than or equal to 75 years of age (relative to those 55 to 64 years of age) and patients with better emotional health had significantly lesser odds of reporting side effects, Patients who were estrogen receptor-positive were less likely to stop taking tamoxifen; patients who experienced side effects were more likely to stop taking tamoxifen.Conclusion: Deviations from a prescribed course of adjuvant tamoxifen occur relatively frequently, The clinical consequences of this deviation need to be identified. J Clin Oncol 19:322-328. (C) 2001 by American Society of Clinical Oncology.